In the brains of AD patients, Gal3 promotes the activation of microglia (Ramirez et al., 2019), and inhibition of Gal3 may be a potential pharmacological method for the treatment of AD (Boza-Serrano et al., 2019). Here, LGALS3 is linked to Alzheimer disease.